ArticleScientific reports2025
The AKT-p21 phosphorylation signaling axis confers poor prognosis and dacarbazine resistance in melanoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Downregulation of Cyclin Kinase Inhibitors p16INK4a and p27 in Conjunctival Melanomas.Investigative ophthalmology & visual science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Understanding the molecular mechanisms underlying melanoma metastasis and chemoresistance is crucial for predicting patients’ prognoses and developing more effective therapies. In this study, we investigated the role of p21 in melanoma progression and treatment resistance. Our findings reveal that increased gene and protein expression of p21 is a strong predictor of poor prognosis in human melanoma, while reducing p21 makes these cells more responsive to chemotherapy. Immunohistochemistry experiments showed higher levels of total and cytoplasmic p21 in metastatic melanoma compared to primary melanomas and other melanocytic lesions. In silico analysis highlighted the interaction of p21 with proteins based on their cellular localization, identifying AKT1 as a potential regulator of p21. This finding corresponds with the observed positive relationship between p21 and AKT1 levels in both melanoma cell lines and patient samples. Significantly, we observed that increased p21 expression, phosphorylation, and translocation to the cytoplasm are associated with resistance to the chemotherapy drug dacarbazine. Accordingly, the overexpression of p21 in a metastatic melanoma cell line led to a further increase in dacarbazine resistance, whereas downregulation of p21 sensitizes these cells to chemotherapy. In addition, both AKT downregulation and the pharmacological inhibition of PI3K diminished p21 phosphorylation, with the former intervention also sensitizing metastasis-prone cells to chemotherapy. Collectively, these findings highlight the critical role of the PI3K/AKT-p21 signaling in the regulation and subcellular localization of p21 in the context of chemotherapy resistance and melanoma prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.